What Groupe PARIMA does

Groupe PARIMA is a privately held Contract Development and Manufacturing Organization (CDMO) founded in 1994 and headquartered in Montreal, Quebec. The company specializes exclusively in non-sterile pharmaceutical dosage forms — semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions — for global pharmaceutical clients ranging from startups to multinational pharmaceutical companies. All operations are conducted from a single 67,000 ft² (6,225 m²) GMP-compliant facility that houses manufacturing suites, temperature-controlled stability chambers, fully equipped analytical laboratories, and ten primary packaging lines, with production capacity rated at 30M+ units annually.

Technically, Groupe PARIMA operates as a vertically integrated CDMO offering formulation development (including pre-formulation studies, de novo development, deformulation, and optimization via QbD/DoE), analytical method development and validation (including IVRT using Franz diffusion cells, microbiology, and ICH stability studies), commercial-scale manufacturing with batch sizes from 5 to 4,000 kg, and primary/secondary packaging including serialization and aggregation. A Class 1 Division 1 explosion-proof manufacturing suite enables safe handling of volatile or alcohol-based formulations, and the Waters Empower 3 chromatography network underpins data integrity across GC, HPLC, UPLC, headspace, and LCMS instruments. Turn-key services encompass raw material sourcing, supplier qualification, supply chain management, cold-chain distribution, and logistics via 3PL partners.

The business model is 100% fee-for-service contract manufacturing and development with no competing product portfolio. Revenue is generated through project-based contracts for clinical and commercial batches across roughly 30+ markets and 45+ countries, with no publicly disclosed pricing. Go-to-market is enterprise sales-led, supported by participation in BIO International Convention, Bio Europe, DCAT Week, Contract Pharma Conference, and CDMO Live, plus a free 1-hour scale-up consulting offering positioned as a lead-generation tool for startup pharma clients. Regulatory standing is a core enabler — the site is favorably inspected by the FDA, EMA, Health Canada, and the Turkish Medicines and Medical Devices Agency, with mutual recognition extending coverage to Medsafe New Zealand and additional jurisdictions.

Name

Groupe PARIMA

Legal name

Groupe PARIMA Inc.

Website

https://groupeparima.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Short description

Groupe PARIMA is a Montreal-based, founder-owned CDMO founded in 1994 that develops and manufactures non-sterile semi-solid, liquid, and suspension pharmaceutical products on a 100% fee-for-service basis for pharmaceutical clients across 45+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract manufacturing
• Non-sterile drug products
• Formulation development services
• GMP manufacturing packaging
• Analytical development testing

Headquarters

HQ city

Saint Laurent

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Fee-for-service contract manufacturing of pharmaceutical products. The company is 100% fee-for-service and exclusively focused on contract services, helping clients meet their objectives without competing with them. Revenue is generated through manufacturing and packaging services for clinical and commercial batches.
2. Pharmaceutical Development Services: Formulation development, process development, tech transfer, and validation services. Includes pre-formulation studies, de novo development, deformulation, formulation optimization, and scale-up support.
3. Analytical Testing Services: In-house analytical laboratory services including method development, validation, transfer, quality control testing (chemistry and microbiology), and stability studies under ICH conditions.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Groupe PARIMA is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures non-sterile semi-solid, liquid, and suspension drug products for oral, topical, nasal, and otic routes of administration. The company operates on a 100% fee-for-service contract basis, offering integrated services spanning formulation development, GMP-compliant manufacturing and packaging, and in-house analytical development and quality control testing. Manufacturing and packaging services support clinical and commercial batches with batch sizes ranging from 5 kg to 4,000 kg, producing up to 30 million units annually for clients across 30+ global markets.

Product overview

Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO) established in 1994, offering an integrated portfolio of pharmaceutical development and manufacturing services. The company's core offerings include Formulation Development (pre-formulation, de novo development, deformulation, and optimization for semi-solids, liquids, and suspensions), Manufacturing & Packaging (GMP-compliant production with batch sizes from 5 to 4,000 kg), and Analytical Development (in-house laboratory for method development, validation, QC testing, and stability studies). Supporting services include Scale-Up Consulting (1-hour free consulting for startups) and ESG+ (sustainability framework). The company specializes in non-sterile dosage forms across semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions. Products are manufactured for over 30 markets globally from the company's 67,000 ft² facility in Montreal, Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation Development Comprehensive formulation development services for non-sterile liquids, semi-solids, and suspensions, including pre-formulation studies, de novo development, deformulation, and formulation optimization using QbD and DoE methodologies. Designed for pharmaceutical companies needing expert support across the development lifecycle.
• Manufacturing & Packaging GMP-compliant pharmaceutical manufacturing and packaging services for non-sterile drug products, including semi-solids (creams, gels, ointments, lotions), liquids, and suspensions, with batch sizes from 5 to 4,000 kg. Turn-key supply chain solutions including serialization and aggregation for global regulatory compliance. Serves pharmaceutical companies requiring commercial-scale production.
• Analytical Development In-house analytical laboratory services including method development, validation, transfer, forced degradation studies, IVRT testing, chemistry and microbiology quality control, and ICH-compliant stability studies. All chromatography performed on Waters Empower 3 network ensuring data integrity for regulatory traceability. Supports pharmaceutical companies with regulatory submissions and routine quality control.
• Scale-Up Consulting One-hour free consulting service for startup pharma companies to navigate scaling from small development batches (as little as 2 kg) to GMP-compliant clinical trial production and commercial scale, including QbD and DoE guidance. Designed to support early-stage pharmaceutical companies with scale-up strategy.

Quantifiable outcome

• 90% Right-First-Time rate for commercial batches
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Hovione: Hovione is a mid-sized CDMO specializing in API synthesis, particle engineering, and drug product manufacturing including semi-solids and oral dosage forms. Comparable as a similarly-sized specialty CDMO with strong technical expertise and global pharmaceutical customer base.
• Tapemark: Tapemark is a contract manufacturer specializing in transdermal patches, topical, and oral dissolvable films, with development and commercial manufacturing services. Comparable as a mid-sized specialty CDMO serving pharmaceutical clients with complex non-sterile dosage forms.
• Cambrex: Cambrex (now owned by Permira) is a CDMO providing active pharmaceutical ingredient development and manufacturing, including small-molecule APIs and finished dosage forms. Comparable as a similarly-sized specialty CDMO serving pharma clients with development through commercial manufacturing capabilities.
• CoreRx: CoreRx is a CDMO offering formulation development, analytical services, and commercial manufacturing for oral solids, liquids, and semi-solids. Comparable given similar focus on small to mid-sized pharma customers and integrated development-to-commercial service offerings.
• Adare Pharma Solutions: Adare Pharma Solutions is a specialty CDMO with deep expertise in oral solid and semi-solid dosage forms, serving similar pharmaceutical customers with formulation development and commercial manufacturing services. Directly comparable as a mid-sized non-sterile-focused CDMO targeting similar therapeutic areas and dosage forms.
• Halo Pharma: Halo Pharma is a CDMO specializing in non-sterile liquid, semi-solid, and oral solid dose manufacturing for small to mid-sized pharmaceutical companies. Highly comparable given similar dosage-form focus, customer profile, and turn-key development-to-commercial service model.

Broad incumbents

• PCI Pharma Services: PCI Pharma Services is a global CDMO providing drug development, manufacturing, and packaging services across multiple dosage forms including liquids and semi-solids. Broader than Groupe PARIMA with sterile capabilities, but overlaps in commercial manufacturing and packaging for similar pharmaceutical customers.
• Catalent: Catalent is one of the largest global CDMOs offering development and manufacturing across oral, sterile, biologic, and inhalation dosage forms. Broader and larger than Groupe PARIMA, but overlaps significantly in oral liquids, semi-solids, and softgel manufacturing for similar pharmaceutical customers.
• Thermo Fisher Scientific (Patheon): Thermo Fisher Scientific acquired Patheon to form a major CDMO franchise offering API, oral solid, sterile, and biologic drug product services globally. Overlaps with Groupe PARIMA in oral liquids, semi-solids, and commercial manufacturing but at vastly greater scale and service breadth.
• Aenova Group: Aenova is a European-based CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing for pharmaceutical and consumer health customers. Comparable as a mid-to-large CDMO serving similar dosage forms and customer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/groupe-parima-inc
• Xx.com/groupeparima

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Groupe PARIMA